Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;97(12):1804-12.
doi: 10.3324/haematol.2012.066159. Epub 2012 Jun 24.

Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies

Haowen Xiao  1 , Yi Luo, Xiaoyu Lai, Shan Fu, Jimin Shi, Yamin Tan, Jingsong He, Wanzhuo Xie, Weiyan Zheng, Li-Mengmeng Wang, Lifei Zhang, Lizhen Liu, Xiujin Ye, Xiaohong Yu, Zhen Cai, Maofang Lin, He Huang
Affiliations

Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies

Haowen Xiao et al. Haematologica. 2012 Dec.

Abstract

Background: Recently, several important polymorphisms have been identified in T-cell activation and effector pathway genes and have been reported to be associated with inter-patient variability in alloimmune responses. The present study was designed to assess the impact of these genetic variations on the outcomes of allogeneic hematopoietic stem cell transplantation.

Design and methods: We first investigated ten single nucleotide polymorphisms in six genes, CD28, inducible co-stimulator, cytotoxic T-lymphocyte antigen 4, granzyme B, Fas and Fas ligand, in 138 pairs of patients and their unrelated donors and a second cohort of 102 pairs of patients and their HLA-identical sibling donors.

Results: We observed that patients receiving stem cells from a donor with the cytotoxic T-lymphocyte antigen 4 gene CT60 variant allele (AA genotype) had a reduced incidence of grades II-IV acute graft-versus-host disease; however, they experienced early cytomegalovirus infection and relapsed more frequently, which suggested an interaction between the donor cytotoxic T-lymphocyte antigen 4 gene CT60 AA genotype and reduced T-cell alloreactivity. Furthermore, an unrelated donor with the granzyme B +55 variant genotype (AA) was an independent risk factor for development of grades II-IV acute graft-versus-host disease (P=0.024, RR=1.811). Among patients with acute myelogenous leukemia, those with the Fas -670 TT genotype were at higher risk of relapse (P=0.003, RR=3.823). The presence of these susceptible alleles in the donor and/or patient resulted in worse overall survival (54.9% versus 69.5%, P=0.029).

Conclusions: Our data suggest that genotype analysis of T-cell activation and effector pathway genes can be used for risk assessment for patients with hematologic malignancies before hematopoietic stem cell transplantation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The capacity for T-cell alloimmune reactivity stratified according to the donors' CTLA-4 CT60 genotype. Cumulative incidence of grades II to IV aGVHD (A), early CMV infection in the URD transplantation cohort (B), early CMV infection in the sibling transplantation cohort (C) and relapse in AML patients (D).
Figure 2.
Figure 2.
Cumulative incidence of grades II to IV aGVHD stratified according to the donors' granzyme B +55 genotypes
Figure 3.
Figure 3.
Cumulative incidence of relapse in AML patients stratified according to the patients' Fas -670 genotypes.
Figure 4.
Figure 4.
Overall survival of patients stratified according to the donors' CTLA-4 CT60 genotype, donors' granzyme B +55 genotype and patients' Fas -670 genotype.
See this image and copyright information in PMC

References

    1. van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010;16(1Suppl):S138-45 - PMC - PubMed
    1. Penack O, Holler E, van den Brink., MR Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010;115(10):1865-72 - PubMed
    1. Rocha V, Porcher R, Fernandes JF, Filion A, Bittencourt H, Silva W, Jr, et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia. 2009;23(3):545-56 - PubMed
    1. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol. 2007;25(27):4262-9 - PubMed
    1. Espinoza JL, Takami A, Onizuka M, Sao H, Akiyama H, Miyamura K, et al. NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fullymatched unrelated bone marrow transplantation for standard risk hematologic malignancies. Haematologica. 2009;94(10):1427-34 - PMC - PubMed

Publication types

MeSH terms